Abstract
Introduction: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification. Methods: Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results: CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion: Our study demonstrated the robustness of a multisite Centiloid [ 11 C]PIB-PET study and established a range of pathology-based CL thresholds.
| Original language | English |
|---|---|
| Pages (from-to) | 205-216 |
| Number of pages | 12 |
| Journal | Alzheimer's & Dementia |
| Volume | 15 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2019 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Alzheimer's disease neuropathologic changes
- Centiloid
- CERAD
- Harmonization
- Neuropathology
- Pittsburgh compound-B
- Positron emission tomography
- Thal
- Threshold
- β-amyloid
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer's & Dementia, Vol. 15, No. 2, 02.2019, p. 205-216.
Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
AU - La Joie, Renaud
AU - Ayakta, Nagehan
AU - Seeley, William W.
AU - Borys, Ewa
AU - Boxer, Adam L.
AU - DeCarli, Charles
AU - Doré, Vincent
AU - Grinberg, Lea T.
AU - Huang, Eric
AU - Hwang, Ji Hye
AU - Ikonomovic, Milos D.
AU - Jack, Clifford
AU - Jagust, William J.
AU - Jin, Lee Way
AU - Klunk, William E.
AU - Kofler, Julia
AU - Lesman-Segev, Orit H.
AU - Lockhart, Samuel N.
AU - Lowe, Val J.
AU - Masters, Colin L.
AU - Mathis, Chester A.
AU - McLean, Catriona L.
AU - Miller, Bruce L.
AU - Mungas, Daniel
AU - O'Neil, James P.
AU - Olichney, John M.
AU - Parisi, Joseph E.
AU - Petersen, Ronald C.
AU - Rosen, Howard J.
AU - Rowe, Christopher C.
AU - Spina, Salvatore
AU - Vemuri, Prashanthi
AU - Villemagne, Victor L.
AU - Murray, Melissa E.
AU - Rabinovici, Gil D.
N1 - Funding Information: Funding: UCSF— National Institutes of Health ( R01-AG045611 , P01-AG1972403 , P50-AG023501 , R01-AG032306 , K24 AG053435 ), Tau Consortium, Consortium for Frontotemporal Dementia Research, John Douglas French Alzheimer's Foundation, and Alzheimer's Association (AARF-16-443577); UCD— National Institutes of Health ( P30 AG010129 , P01 AG012435 , R01 AG021028 , R01 AG031563 ); UC Berkeley— National Institute of Health ( R01AG034570 ); Mayo— National Institutes of Health ( R01 NS097495 , U01 AG006786 , P50 AG016574/P1 , R01 AG011378 , R01 AG041851 , R01 AG054449 ), the GHR Foundation, the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation , Liston Award, Elsie and Marvin Dekelboum Family Foundation, and Schuler Foundation. AIBL— NHMRC Research Fellowship 1046471, NHMRC Program Grant 1132604; and UPitt: National Institute of Health (P50 AG005133, RF1 AG025516, P01 AG025204). Funding Information: Funding: UCSF?National Institutes of Health (R01-AG045611, P01-AG1972403, P50-AG023501, R01-AG032306, K24 AG053435), Tau Consortium, Consortium for Frontotemporal Dementia Research, John Douglas French Alzheimer's Foundation, and Alzheimer's Association (AARF-16-443577); UCD?National Institutes of Health (P30 AG010129, P01 AG012435, R01 AG021028, R01 AG031563); UC Berkeley?National Institute of Health (R01AG034570); Mayo?National Institutes of Health (R01 NS097495, U01 AG006786, P50 AG016574/P1, R01 AG011378, R01 AG041851, R01 AG054449), the GHR Foundation, the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation, Liston Award, Elsie and Marvin Dekelboum Family Foundation, and Schuler Foundation. AIBL?NHMRC Research Fellowship 1046471, NHMRC Program Grant 1132604; and UPitt: National Institute of Health (P50 AG005133, RF1 AG025516, P01 AG025204).Disclosures: GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. Drs. Klunk and Mathis are co-inventors of PIB and, as such, have a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. Dr. Boxer receives research support from Avid, Biogen, Bristol Myers Squibb, C2N Diagnostics, Cortice Biosciences, Eli Lilly, Forum Pharmaceuticals, Genentech, and TauRx. He has served as a consultant for Asceneuron, iPierian, Isis, Janssen, and Merck. He has stock/options in Alector and Delos. Lea T. Grinberg receives research support from Avid Radiopharmaceuticals and Eli Lilly and served as a consultant to GlaxoSmithKline. Dr. Ikonomovic served as a consultant and received research funding from GE Healthcare. Dr. Jagust has served as a consultant to BioClinica, Genentech, and Novartis Pharmaceuticals. Dr. Lowe serves as a consultant for Bayer Schering Pharma and Piramal Imaging and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, the NIH (NIA, NCI), and the MN Partnership for Biotechnology and Medical Genomics. Dr. Petersen served as a consultant for Roche, Inc, Merck, Inc., Genentech, Inc., and Biogen, Inc. Dr. Rabinovici receives research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, and Piramal. He has received consulting fees from Genentech, Merck, and Roche. Funding Information: Disclosures: GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. Drs. Klunk and Mathis are co-inventors of PIB and, as such, have a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. Dr. Boxer receives research support from Avid, Biogen, Bristol Myers Squibb, C2N Diagnostics, Cortice Biosciences, Eli Lilly, Forum Pharmaceuticals, Genentech, and TauRx. He has served as a consultant for Asceneuron, iPierian, Isis, Janssen, and Merck. He has stock/options in Alector and Delos. Lea T. Grinberg receives research support from Avid Radiopharmaceuticals and Eli Lilly and served as a consultant to GlaxoSmithKline. Dr. Ikonomovic served as a consultant and received research funding from GE Healthcare. Dr. Jagust has served as a consultant to BioClinica, Genentech, and Novartis Pharmaceuticals. Dr. Lowe serves as a consultant for Bayer Schering Pharma and Piramal Imaging and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, the NIH (NIA, NCI), and the MN Partnership for Biotechnology and Medical Genomics. Dr. Petersen served as a consultant for Roche, Inc, Merck, Inc., Genentech, Inc., and Biogen, Inc. Dr. Rabinovici receives research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, and Piramal. He has received consulting fees from Genentech, Merck, and Roche. Funding Information: Disclosures: GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. Drs. Klunk and Mathis are co-inventors of PIB and, as such, have a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. Dr. Boxer receives research support from Avid, Biogen , Bristol Myers Squibb, C2N Diagnostics, Cortice Biosciences, Eli Lilly , Forum Pharmaceuticals, Genentech , and TauRx. He has served as a consultant for Asceneuron, iPierian, Isis, Janssen, and Merck. He has stock/options in Alector and Delos. Lea T. Grinberg receives research support from Avid Radiopharmaceuticals and Eli Lilly and served as a consultant to GlaxoSmithKline . Dr. Ikonomovic served as a consultant and received research funding from GE Healthcare. Dr. Jagust has served as a consultant to BioClinica, Genentech , and Novartis Pharmaceuticals. Dr. Lowe serves as a consultant for Bayer Schering Pharma and Piramal Imaging and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, the NIH (NIA, NCI), and the MN Partnership for Biotechnology and Medical Genomics. Dr. Petersen served as a consultant for Roche, Inc , Merck, Inc. , Genentech, Inc. , and Biogen, Inc . Dr. Rabinovici receives research support from Avid Radiopharmaceuticals, Eli Lilly , GE Healthcare, and Piramal. He has received consulting fees from Genentech , Merck , and Roche. Publisher Copyright: © 2018 the Alzheimer's Association
PY - 2019/2
Y1 - 2019/2
N2 - Introduction: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification. Methods: Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results: CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion: Our study demonstrated the robustness of a multisite Centiloid [ 11 C]PIB-PET study and established a range of pathology-based CL thresholds.
AB - Introduction: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification. Methods: Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results: CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion: Our study demonstrated the robustness of a multisite Centiloid [ 11 C]PIB-PET study and established a range of pathology-based CL thresholds.
KW - Alzheimer's disease neuropathologic changes
KW - Centiloid
KW - CERAD
KW - Harmonization
KW - Neuropathology
KW - Pittsburgh compound-B
KW - Positron emission tomography
KW - Thal
KW - Threshold
KW - β-amyloid
UR - https://www.scopus.com/pages/publications/85057067485
U2 - 10.1016/j.jalz.2018.09.001
DO - 10.1016/j.jalz.2018.09.001
M3 - Article
C2 - 30347188
AN - SCOPUS:85057067485
SN - 1552-5260
VL - 15
SP - 205
EP - 216
JO - Alzheimer's & Dementia
JF - Alzheimer's & Dementia
IS - 2
ER -